

# **Relationship between monocyte-platelet aggregation and endothelial function in middle-aged and elderly adults**

Andrew Haynes<sup>1</sup>  
Matthew D Linden<sup>2</sup>  
Elisa Robey<sup>1</sup>  
Louise H Naylor<sup>1</sup>  
Kay L Cox<sup>1,5</sup>  
Nicola T Lautenschlager<sup>6,7,8</sup>  
Daniel J Green<sup>1,3,4</sup>

<sup>1</sup>School of Sport Science, Exercise and Health, University of Western Australia,  
Crawley, Western Australia

<sup>2</sup>School of Pathology and Laboratory Medicine, University of Western Australia,  
Crawley, Western Australia

<sup>3</sup>Research Institute for Sport and Exercise Science, Liverpool John Moores University,  
Liverpool, United Kingdom

<sup>4</sup>Principal Research Fellow, National Health and Medical Research Council, Australia

<sup>5</sup>School of Medicine and Pharmacology (Royal Perth Hospital Unit), University of Western  
Australia, Western Australia

<sup>6</sup>Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of  
Melbourne, Victoria, Australia

<sup>7</sup>NorthWestern Mental Health, Melbourne Health, Parkville, Victoria, Australia

<sup>8</sup>School of Clinical Neurosciences and the Western Australia Centre for Health and Ageing,  
University of Western Australia, Crawley, Western Australia

**Running Head:** Platelet function and flow mediated dilation

## **Author for Correspondence**

Winthrop Professor Daniel J Green  
35 Stirling Hwy, School of Sports Science, Exercise and Health  
The University of Western Australia, Crawley, Western Australia, 6009  
Phone: +61 (8) 6488 2378, Fax: +61 (8) 6488 1039  
Email: [danny.green@uwa.edu.au](mailto:danny.green@uwa.edu.au)

## Abstract

Low grade inflammation, endothelial dysfunction and platelet hyper-reactivity to agonists are associated with an increased risk of cardiovascular events. In vitro and animal studies infer an inverse mechanistic relationship between platelet activation and the production of endothelium-derived nitric oxide and prostacyclin. This concept is supported by evidence of an inverse relationship between endothelial function and platelet activation in high-risk cardiac patients. The aim of the present study was to investigate what relationship, if any, exists between platelet and endothelial function in healthy, middle-aged and elderly adults. In fifty one participants (18 male, 33 post-menopausal female), endothelial function was assessed by flow mediated dilation (FMD). Platelet function was assessed by flow cytometric determination of glycoprotein IIb/IIIa activation (measured by PAC-1 binding), granule exocytosis (measured by surface P-selectin expression) and monocyte-platelet aggregates (MPAs), with and without stimulation by canonical platelet agonists adenosine diphosphate (ADP), arachidonic acid (AA) and collagen. Correlation analysis indicated there was no significant (all  $P \geq 0.05$ ) relationship between FMD and any marker of *in vivo* platelet activation (MPAs  $R = 0.193$ , PAC-1  $R = -0.113$ , anti-CD62P  $R = -0.078$ ) or inducible platelet activation by ADP (MPA  $R = -0.128$ , anti-CD62P  $R = -0.237$ ), AA (MPA  $R = -0.122$ , PAC-1  $R = -0.045$ , anti-CD62P  $R = -0.142$ ) or collagen (MPA  $R = 0.136$ , PAC-1  $R = 0.174$ , anti-CD62P  $R = -0.077$ ). Our findings contrast with two previous studies performed in high risk cardiac patients, which reported inverse relationships between platelet activation and endothelial function, suggesting that some compensatory redundancy may exist in the relationship between platelet and endothelial function in pre-clinical populations.

## **New & Noteworthy**

In this study which included healthy middle-aged and elderly adults, we compared measures of *in vivo* endothelial function and platelet activation, risk factors for cardiovascular disease that are inversely associated in high-risk cardiac patients. Some compensatory redundancy may exist in these variables in pre-clinical populations.

**Key Words:** endothelial function, platelet function, cardiovascular disease

## Introduction

Thrombosis is an integral component of acute coronary syndromes such as acute myocardial infarction (MI) and ischemic stroke (12, 23). Moreover, the role of platelets in the early, dormant stages of atherosclerosis and cardiovascular disease (CVD) has recently been recognized (26, 40). Low grade inflammation, endothelial dysfunction and platelet hyper-reactivity to agonists are all independently associated with an increased risk of cardiovascular events (15, 24). An intact and healthy endothelium regulates and inhibits platelet activation (9) and endothelial dysfunction may play a direct role in activating platelets (8). Platelet activation results in the formation of monocyte-platelet aggregates (MPAs) (27), and stepwise increases in MPAs and activated platelets have been observed with cardiovascular disease progression (28). The interaction between activated platelets and monocytes can initiate the release of pro-inflammatory and adhesive molecules that are atherogenic (13, 30, 32, 50), driving a pro-atherogenic monocytic phenotype (4) and facilitating the infiltration of monocytes to the sub-intima space (30, 47).

A number of *in vitro* experiments suggest that nitric oxide (NO) and prostacyclin (PGI<sub>2</sub>), produced by endothelial cells, directly inhibit platelet aggregation (2, 3, 29). However, the functional relationship between platelet activation and endothelial function *in vivo* is less clear (31, 38). Whilst inhibition of NO production in healthy young adults can increase platelet activation (42) and decrease clotting time (44), this is not a universal finding (1) and these studies assessed the acute impact of pharmacological blockade. An inverse relationship between endothelium-dependent coronary vasomotor function and MPAs measured in arterial samples has been documented in high risk patients undergoing cardiac angiography and angioplasty (11, 17). There is also evidence to suggest that pharmacological blockade of the

platelet fibrinogen receptor (glycoprotein IIb/IIIa receptor) (18) and administration of the anti-platelet medications clopidogrel (16, 35, 37, 46) and aspirin (20, 48) can acutely improve endothelial function in patients with CAD. However, these short term effects were abolished when administration was maintained for longer periods of time (36). One previous study (22) has investigated the relationship between *in vivo* endothelial function, assessed using brachial artery flow mediated dilation (FMD) and platelet function assessed via flow cytometry (14). This study was conducted in adolescents, with or without a positive family history of CAD, and no relationship was found between FMD and platelet activation (MPAs, PAC-1 or CD62P binding).

Increasing age and physical inactivity are risk factors for cardiovascular disease (43), but no previous study, to our knowledge, has investigated relationships between endothelial function and platelet activation in asymptomatic healthy older adults, or whether any such relationship extends to agonist-induced platelet activation. Therefore, our aim was to test the relationship, if any, between platelet and endothelial function in apparently healthy, physically inactive, middle-aged and elderly humans. We hypothesized that FMD would be inversely associated with the presence of MPAs and activated platelets; and inversely associated with agonist-induced platelet activation.

## **Materials and Methods**

The study was approved by the University of Western Australia Human Research Ethics Committee, procedures were in accord with the Declaration of Helsinki and participants provided written informed consent.

Male and post-menopausal female participants were recruited from the general population in Perth, Western Australia using multiple recruitment strategies including advertisements in local newspapers, radio stations and posters. Apparently healthy individuals aged 45yrs and over were encouraged to contact the research team, resulting in initial phone screening procedures which included questionnaires to determine suitability to attend a formal screening visit. Initial exclusion criteria included serious illness such as cancer, diagnosed cognitive impairment or dementia, current or past history of ischemic heart disease, angina, stroke, persistent arrhythmias, diabetes mellitus, airway disease, epilepsy, severe mental illness, engaging in more than 1 hour of physical activity per week, current or recent smokers (within 12 months), pre- or peri-menopausal females and alcohol consumption >28 standard drinks/wk.

Individuals satisfying the initial criteria were invited to attend a screening session during which a number of measures were collected including: height, body mass, resting electrocardiogram (ECG) and fasting blood tests (glucose, lipid profile, full blood count, urea and electrolytes). Participants exhibiting abnormal cardiac rhythms, blood test results suggestive of chronic kidney disease, diabetes, or total cholesterol >7mmol/L were excluded. Included participants were then invited to perform an exercise stress test with ECG monitoring and those with evidence of exertion-induced myocardial ischemia were excluded from further participation. In subsequent visits, participants underwent a 20 minute resting blood pressure (BP) assessment and a dual energy x-ray absorptiometry (DEXA) scan. For the resting BP assessment, participants arrived at the laboratory in the morning following an overnight fast and lay in a supine position in a temperature controlled dark room. BP was

measured every 2 minutes by an automated device (Dinamap V100, GE Healthcare, USA). Individuals with an average systolic BP >160mmHg or diastolic BP >100mmHg were excluded.

For flow mediated dilation (FMD) and platelet function tests, participants arrived at the laboratory in the morning between 7:00-9:30am, following an overnight fast, having abstained from the consumption of caffeine and alcohol for 12 and 24 hours respectively and not taken part in physical exercise for 24 hours. Adherence to the protocol was confirmed by questionnaire on arrival. Prior to attending the laboratory for data collection, participants were instructed to be clear of symptoms for 7 days if they had recently suffered with acute conditions including respiratory tract infection, cold and flu. Participants taking prescription medications were instructed to maintain their usual routine of administration. However, the use of non-prescribed medications such as anti-inflammatory, anti-histamine, antibiotic, aspirin, cold and flu medications were ceased for at least 7 days prior to blood collection. Participants lay supine in a cool temperature controlled room for 15 minutes, after which a blood sample was collected from the dominant arm for the assessment of platelet function. Subsequent FMD tests were performed on the non-dominant arm.

### *Blood Collection*

A venous blood sample was collected into a 4mL 3.2% sodium citrate tube (Vacurette by Greiner bio-one) and processed according to published standards (27), as pre-analytical variables during blood collection, storage and handling are an important factor in platelet

function testing. Within 10 minutes of collection, blood was processed to assess circulating levels of MPAs and activated platelets and their sensitivity to platelet agonists.

#### *Monocyte-platelet aggregates*

Each MPA reaction tube included two antibodies: CD14 (monocyte identifier) conjugated to the fluorophore Brilliant Violet (BV) 421 (Clone M5E2, BioLegend, San Diego CA) and CD42b (platelet identifier) conjugated to Allophycocyanin (APC) (Clone HIP1, BioLegend) or IgG isotype control (BioLegend). Six MPA reaction tubes (Protein LoBind Eppendorf, Germany) were included: isotype control, no agonist, positive control (250 $\mu$ M thrombin receptor activating peptide-6 (SFLLRN, Sigma-Aldrich, MO)), and threshold (low) concentrations of the following three agonists: adenosine diphosphate (ADP) 1.5 $\mu$ M (Chrono-Log Corp., PA), arachidonic acid (AA) 10 $\mu$ g/mL (Sodium arachidonate, Bio/Data Corp., PA) and collagen 1.5 $\mu$ g/mL (Chrono-Log Corp., PA). Absence of spectral overlap was confirmed by single-colour comp bead controls (BD Biosciences). Samples were fixed and red cells lysed with 800 $\mu$ L of BD FACSLyse solution (BD Biosciences) following exactly 15 minutes of incubation. Samples were then stored in the dark at 4°C and analyzed by flow cytometry (BD FACSCanto™ II, BD Biosciences) at a low flow rate for 10 minutes per tube, to avoid coincident events (19).

#### *Platelet surface receptors*

Whole blood was diluted 1:5 with HEPES saline buffer and incubated with a cocktail of the following fluorescent conjugated antibodies at saturating concentrations: PAC-1 fluorescein (FITC), CD62P phycoerythrin (PE), CD42b PE-Cy5, or IgG1K PE isotype control (all BD



Pharmingen) for exactly 15 minutes. Six reaction tubes were used that were identical in function and agonist concentrations as those used for MPAs. However, ADP at the concentration used (1.5 $\mu$ M) caused maximal PAC-1 binding in all participants, so was not included in statistical analysis. Following incubation, samples were fixed with 800 $\mu$ L of stabilizing fixative (BD Biosciences) and were then stored at 4°C until analysis by flow cytometry (BD FACSCanto II) within 24 hours. Samples were run at a low flow rate until 10,000 platelet positive events were counted. To account for spectral overlap between the three fluorophores, single stained compensation beads were used (BD Biosciences). For both MPAs and platelet surface receptor binding, samples were incubated at room temperature with the exception of tubes containing AA and collagen, which were incubated at 37°C using a dry block heater (Ratek DBH20D, Victoria, Australia).

#### *Flow mediated dilation (FMD)*

The vascular assessments were conducted in a quiet, temperature-controlled room in accordance to recent guidelines (45). To examine brachial artery FMD, the non-dominant arm was extended and positioned at an angle of ~80° from the torso. A rapid inflation and deflation pneumatic cuff (D.E. Hokanson, Bellevue, WA, USA) was positioned on the forearm, immediately distal to the olecranon process to provide a forearm ischemia stimulus. Using this approach, the brachial artery dilation represents a largely NO-mediated, endothelium-dependent response (14). A 10-MHz multi-frequency linear array probe, attached to a high-resolution ultrasound machine (T3200; Terason, Burlington, MA, USA) was used to image the brachial artery in the distal 1/3rd of the upper arm. When an optimal image was obtained, the probe was held stable and the ultrasound parameters were set to optimise the longitudinal, B-mode images of lumen–arterial wall interface. Continuous

Doppler velocity assessments were also obtained using the ultrasound, and were collected using the lowest possible insonation angle (always  $<60^\circ$ ). Following a 1-min baseline recording of brachial artery diameter and velocity (Camtasia Studio 8, TechSmith, Okemos, MI), which were used to examine baseline blood flow patterns, the forearm cuffs were inflated (220mmHg) for 5 min. Diameter and flow recordings resumed 30s prior to cuff deflation and continued for 3 min thereafter. Post-test analysis of brachial artery diameter was performed using custom-designed edge-detection and wall-tracking software, which is largely independent of investigator bias (49). Brachial artery FMD is presented as relative (%) rise from the preceding baseline diameter. We have shown that the reproducibility of diameter measurements using this semi-automated software is significantly better than manual methods, reduces observer error significantly, and possesses an intra-observer CV of 6.7%.

### *Statistical Methods*

To test whether there was a relationship between FMD and platelet function, a Pearson product-moment correlation test was carried out for data that were normally distributed. For data that were not normally distributed, a Spearman's Rank test was conducted. Subsequently, to determine if potential confounding factors including: age, gender, resting heart rate and blood pressure, body fat percentage, fasting blood glucose and lipids, and medication use impacted upon the results, partial correlations were conducted to account for these co-variates. Participants were then divided into 2 groups based on gender, and correlation analysis between FMD and platelet function was conducted for males and females separately to determine if results were gender specific. To test whether any differences existed between male and female participants for FMD or any of the platelet function

variables measured, independent sample T-tests and Mann-Whitney U tests were conducted for data meeting and failing normality assumptions respectively.

## **Results**

Fifty one participants (18 male, 33 female) were included in the study and underwent platelet function and FMD tests. The general characteristics of participants included in the study are presented in Table 1. Two participants failed to receive a DEXA scan, so for data derived using this outcome measure  $n=49$ . Descriptive statistics for vascular and platelet function outcome measures can be seen in Table 2. An error in the processing of platelet PAC-1 and CD62P with no agonist occurred for 1 participant and for PAC-1 and CD62P with AA incubation for 1 other participant. Therefore, for the direct comparison of all MPA data vs FMD  $n=51$ , but for PAC-1 and CD62P NA and AA  $n=50$ .

### *Relationships between FMD and platelet activation*

No significant relationship was found between FMD% and circulating levels of activated platelets, whether measured by MPAs (Figure 1), PAC-1 (Figure 2) or anti-CD62P (Figure 3) binding (all  $P > 0.05$ ). No relationship was observed between FMD% and platelet reactivity to the agonists ADP (MPA & CD62P only), AA or collagen for MPAs, PAC-1 or anti-CD62P binding (all  $P > 0.05$ ). All correlation results can be found in Table 2.

### *Impact of potential confounding variables*

Inspection of scatter plots suggested that no linear relationship existed between any of the potential confounding variables (age, gender, resting heart rate, blood pressure, % body fat, fasting glucose and lipids (triglycerides, cholesterol, LDL and HDL) and medication use) and FMD% or any of the platelet function parameters. Consequently, the results of partial correlation testing indicated that no significant relationship (all  $P > 0.05$ ) existed between FMD% and any of the measures of platelet function we studied when these potentially confounding variables were included as co-factors (see Table 3).

### *Potential gender differences*

Independent correlation analyses conducted for male and female participants individually revealed there were no significant relationships between FMD and any of the platelet function variables we measured for either gender (all  $P = > 0.05$ ). No significant differences were found between male and female participants for FMD ( $P = 0.767$ ), MPA NA ( $P = 0.554$ ), MPA ADP ( $P = 0.577$ ), MPA AA ( $P = 0.419$ ), MPA collagen ( $P = 0.608$ ), PAC-1 NA ( $P = 0.928$ ), PAC-1 AA ( $P = 0.524$ ), PAC-1 collagen ( $P = 0.150$ ), CD62P NA ( $P = 0.146$ ), CD62P ADP ( $P = 0.585$ ), CD62P AA ( $P = 0.565$ ), CD62P collagen ( $P = 0.086$ ).

## Discussion

Endothelial dysfunction and increased platelet activation are both associated with cardiovascular disease progression (9, 10) and, based on *in vitro* and animal studies, it is often inferred that a direct and inverse relationship exists between the function of the endothelium and platelet activation (2, 3, 41, 42). The aim of the present study was to investigate the relationship between endothelial function and platelet activation in a pre-clinical low-risk population of older participants with low physical activity levels. In this study, we did not find any relationship between flow mediated dilation, an indicator of endogenous nitric oxide and prostacyclin bioavailability (14), and platelet function assessed by flow cytometry.

Our findings were unexpected, as the extant literature suggests there is an inverse relationship between platelet and endothelial function (11, 16-18, 20, 35, 37, 41, 42, 46). In contrast to our study, two previous investigations have reported an inverse relationship between vascular function and MPAs in high-risk cardiac patients (11, 17). These studies utilized highly invasive vascular tests (coronary vasomotor function) and measured platelet activation in arterial blood samples. We tested endothelial function in the brachial artery following established guidelines, a common and reproducible approach (34, 45). Platelet function was interrogated in venous blood samples with multiple outcomes (ie MPAs, PAC-1 and anti-CD62P binding), with and without canonical platelet agonists, using sophisticated and established flow cytometry techniques (27) which have been associated with cardiovascular outcome. It is possible that differences in participant characteristics and/or methodological approaches between our study and these previous reports are responsible for the divergent findings. In critically ill patients with sepsis, MPAs in arterial blood were ~60% greater

compared to MPAs in venous blood (39), but to our knowledge no investigation has determined if sampling technique confers physiological or pathological relevance, or if such a difference exists in healthy individuals.

The majority of studies that have reported an inverse relationship between platelets and endothelial function have involved pharmacological modulation of these variables using acute experiments in humans (16, 18, 20, 35, 37, 42, 46). In one such study, platelet activation was increased by blockade of endothelium-derived nitric oxide using a bolus dose of N<sup>G</sup>-monomethyl-L-arginine (42), whereas lower doses of blockade did not induce such changes (1). Likewise, increases in FMD have been observed following a single loading dose of clopidogrel and vasodilation responses post-administration were dose-dependent (46). Research in which a significant association was observed between platelet and endothelial function has involved participants with established coronary disease undergoing cardiac angiography and angioplasty. Such individuals exhibit large changes in platelet activation and endothelial function (12, 28) and possess an inflammatory state (25) that may partly explain the inverse relationship observed. In contrast, there is some evidence to suggest up-regulation of NO-synthase mediated endothelial function occurs in the presence of CVD risk factors (7, 33) and it is possible that, in sub-clinical and apparently healthy populations with risk factors for CVD, some compensatory redundancy exists in the interaction between the endothelium and platelets. This could account for the lack of an inverse relationship between these two variables in our study. Furthermore, there is some evidence to suggest that compensatory mechanisms that prevent spontaneous thrombosis and preserve hemostatic function occur in mice incapable of producing NO (21). Indeed, the percentage of circulating MPAs in our cohort ( $4.1 \pm 1.4$  %) were far lower than that reported in samples taken from high risk cardiac

(~20-38%) (11, 17) and stable CAD (~12%) patients (28), even after considering the potential differences in MPAs between arterial and venous blood (39).

Our findings do not necessarily conflict with the established role of platelet and endothelial function in atherosclerosis, highlighted in recent reviews (6, 9, 30). However, because atherosclerosis evolves slowly over many decades in humans, it is possible that the relationship between endothelial and platelet function in healthy individuals is less apparent and/or detectable, even with the sensitive technical approaches used in the present study. In contrast, transgenic mouse models provide a relatively accelerated and exaggerated insight into disease pathogenesis (5). Diabetic mice with lower NO bioavailability exhibit higher basal levels of activated platelets compared to control mice (41), whereas mice with induced diabetes but preserved NO-bioavailability due to over-expression of tetrahydrobiopterin possess normal levels of activated platelets. These findings suggest that in accelerated pathological models and/or in certain advanced disease states (eg CAD, diabetes mellitus), increased platelet activation and reduced endothelial NO may be mechanistically relevant. Although we deliberately recruited healthy middle-aged and elderly individuals in this study, future research should include a wide range of participants, across the lifespan. A potential limitation to the current study is the limited sample size, but previous studies which have reported a significant inverse relationship between FMD and platelet activation have included 30 (11) and 19 (17) patients, so this is unlikely to be responsible for the lack of relationship in the current study.

There are several limitations to our study. We constrained recruitment to >45yrs and all women were post-menopausal. Our average FMD results indicate a relatively lower response

than studies involving younger cohorts, in keeping with the established impact of age on vascular function. Nonetheless, we cannot generalize our findings to younger or much older age groups. Similarly, our study excluded participants with established cardiovascular diseases and, as mentioned above, correlations between platelet and endothelial function may be more apparent in those with overt disease. Finally, whilst some of our participants were taking medications, sub-group analysis revealed no impact of drugs on the magnitude or pattern of correlation in our study. Notably, all participants taking medications specifically known to impact upon platelet function were excluded from our study.

In summary, we did not observe any relationship between endothelial function and platelet activation in the healthy, middle-aged and elderly participants we recruited in this study. As our findings contrast with some previous studies conducted in high risk cardiac patients, our data suggest that some compensatory redundancy may exist in the relationship between platelet and endothelial function in pre-clinical populations.



## **Acknowledgements**

The authors acknowledge the facilities, and the scientific and technical assistance of the Australian Microscopy & Microanalysis Research Facility at the Centre for Microscopy, Characterisation & Analysis, The University of Western Australia, a facility funded by the University, State and Commonwealth Governments.

## **Grants**

This work was supported by funding from the National Heart Foundation of Australia G12P6417 and National Health and Medical Research Council (NHMRC) APP1045204.

Professor Green is a National Health and Medical Research Council Principal Research Fellow (APP1080914).

Associate Professor Linden is an International Society for Advancement of Cytometry (ISAC) Marylou Ingram Scholar.

## **Disclosures**

None.

## References

1. **Albert J, Wallen NH, Nailin L, Frostell C, and Hjemdahl P.** Neither endogenous nor inhaled nitric oxide influences the function of circulating platelets in healthy volunteers. *Clinical Science* 97: 345-353, 1999.
2. **Alheid U, Frölich JC, and Förstermann U.** Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets. *Thrombosis Research* 47: 561-571, 1987.
3. **Alheid U, Reichwehr I, and Förstermann U.** Human endothelial cells inhibit platelet aggregation by separately stimulating platelet cyclic AMP and cyclic GMP. *European Journal of Pharmacology* 164: 103-110, 1989.
4. **Barnard MR, Linden MD, Frelinger A, Li Y, Fox ML, Furman MI, and Michelson AD.** Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. *Journal of Thrombosis and Haemostasis* 3: 2563-2570, 2005.
5. **Breslow JL.** Mouse models of atherosclerosis. *Science* 272: 685, 1996.
6. **Cahill PA, and Redmond EM.** Vascular endothelium—Gatekeeper of vessel health. *Atherosclerosis* 248: 97-109, 2016.
7. **Cosentino F, Hishikawa K, Katusic ZS, and Lüscher TF.** High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. *Circulation* 96: 25-28, 1997.
8. **Davì G, Guagnano MT, Ciabattini G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, and Patrono C.** Platelet activation in obese women: role of inflammation and oxidant stress. *JAMA* 288: 2008-2014, 2002.
9. **Davì G, and Patrono C.** Platelet activation and atherothrombosis. *New England Journal of Medicine* 357: 2482-2494, 2007.

10. **Davignon J, and Ganz P.** Role of endothelial dysfunction in atherosclerosis. *Circulation* 109: III-27-III-32, 2004.
11. **Di Serafino L, Sarma J, Dierickx K, Ntarladimas I, Pyxaras SA, Delrue L, De Bruyne B, Wijns W, Barbato E, and Bartunek J.** Monocyte–Platelets Aggregates as Cellular Biomarker of Endothelium-Dependent Coronary Vasomotor Dysfunction in Patients with Coronary Artery Disease. *Journal of Cardiovascular Translational Research* 7: 1-8, 2014.
12. **Falk E, Nakano M, Bentzon JF, Finn AV, and Virmani R.** Update on acute coronary syndromes: the pathologists' view. *European Heart Journal* 34: 719-728, 2013.
13. **Gerdes N, Seijkens T, Lievens D, Kuijpers MJ, Winkels H, Projahn D, Hartwig H, Beckers L, Megens RT, and Boon L.** Platelet CD40 Exacerbates Atherosclerosis by Transcellular Activation of Endothelial Cells and Leukocytes. *Arteriosclerosis, Thrombosis, and Vascular Biology* 36: 482-490, 2016.
14. **Green DJ, Jones H, Thijssen D, Cable N, and Atkinson G.** Flow-mediated dilation and cardiovascular event prediction does nitric oxide matter? *Hypertension* 57: 363-369, 2011.
15. **Gurbel PA, Becker RC, Mann KG, Steinhubl SR, and Michelson AD.** Platelet Function Monitoring in Patients With Coronary Artery Disease. *Journal of the American College of Cardiology* 50: 1822-1834, 2007.
16. **Hamilos M, Muller O, Ntalianis A, Trana C, Bartunek J, Sarno G, Mangiacapra F, Dierickx K, Meeus P, and Cuisset T.** Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. *Journal of Thrombosis and Thrombolysis* 32: 64-71, 2011.
17. **Hamilos M, Sarma J, Ostojic M, Cuisset T, Sarno G, Melikian N, Ntalianis A, Muller O, Barbato E, and Beleslin B.** Interference of Drug-Eluting Stents With

Endothelium-Dependent Coronary Vasomotion Evidence for Device-Specific Responses.

*Circulation: Cardiovascular Interventions* 1: 193-200, 2008.

18. **Heitzer T, Ollmann I, Köke K, Meinertz T, and Munzel T.** Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease. *Circulation* 108: 536-541, 2003.

19. **Hui H, Fuller K, Erber WN, and Linden MD.** Measurement of monocyte- platelet aggregates by imaging flow cytometry. *Cytometry Part A* 87: 273-278, 2015.

20. **Husain S, Andrews NP, Mulcahy D, Panza JA, and Quyyumi AA.** Aspirin improves endothelial dysfunction in atherosclerosis. *Circulation* 97: 716-720, 1998.

21. **Iafrati MD, Vitseva O, Tanriverdi K, Blair P, Rex S, Chakrabarti S, Varghese S, and Freedman JE.** Compensatory mechanisms influence hemostasis in setting of eNOS deficiency. *American Journal of Physiology-Heart and Circulatory Physiology* 288: H1627-H1632, 2005.

22. **Lanza GA, Scalone G, Barone L, Infusino F, Coviello I, Di Monaco A, Delogu A, Battipaglia I, De Nisco A, Sestito A, Romagnoli C, and Crea F.** Platelet reactivity and endothelial function in children of patients with early acute myocardial infarction. *European Heart Journal* 32: 2042-2049, 2011.

23. **Libby P.** Mechanisms of acute coronary syndromes and their implications for therapy. *New England Journal of Medicine* 368: 2004-2013, 2013.

24. **Libby P, Nahrendorf M, and Swirski FK.** Monocyte heterogeneity in cardiovascular disease. In: *Seminars in immunopathology*, Springer, 2013, p. 553-562.

25. **Libby P, Ridker PM, Hansson GK, and Leducq Transatlantic Network on A.** Inflammation in atherosclerosis: from pathophysiology to practice. *Journal of the American College of Cardiology* 54: 2129-2138, 2009.

26. **Lievens D, and von Hundelshausen P.** Platelets in atherosclerosis. *Thrombosis and Haemostasis* 106: 827-838, 2011.
27. **Linden MD.** Platelet flow cytometry. *Haemostasis: Methods and Protocols* 241-262, 2013.
28. **Linden MD, Furman MI, Frelinger A, Fox ML, Barnard MR, Li Y, Przyklenk K, and Michelson AD.** Indices of platelet activation and the stability of coronary artery disease. *Journal of Thrombosis and Haemostasis* 5: 761-765, 2007.
29. **Macdonald P, Read M, and Dusting G.** Synergistic inhibition of platelet aggregation by endothelium derived relaxing factor and prostacyclin. *Thrombosis Research* 49: 437-449, 1988.
30. **McFadyen JD, and Kaplan ZS.** Platelets are not just for clots. *Transfusion Medicine Reviews* 29: 110-119, 2015.
31. **Megson IL, Sogo N, Mazzei FA, Butler AR, Walton JC, and Webb DJ.** Inhibition of human platelet aggregation by a novel S- nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti- thrombotic therapy. *British Journal of Pharmacology* 131: 1391-1398, 2000.
32. **Michelson AD, Barnard MR, Krueger LA, Valeri CR, and Furman MI.** Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin studies in baboons, human coronary intervention, and human acute myocardial infarction. *Circulation* 104: 1533-1537, 2001.
33. **Minor Jr RL, Myers PR, Guerra Jr R, Bates JN, and Harrison D.** Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. *Journal of Clinical Investigation* 86: 2109, 1990.

34. **Mosawy S, Jackson DE, Woodman OL, and Linden MD.** Inhibition of platelet-mediated arterial thrombosis and platelet granule exocytosis by 3',4'-dihydroxyflavonol and quercetin. *Platelets* 24: 594-604, 2012.
35. **Muller O, Hamilos M, Bartunek J, Ulrichs H, Mangiacapra F, Holz J-B, Ntalianis A, Trana C, Dierickx K, and Vercruysse K.** Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. *The American Journal of Cardiology* 105: 333-338, 2010.
36. **Ostad MA, Nick E, Paixao-Gatinho V, Schnorbus B, Schiewe R, Tschentscher P, Munzel T, and Warnholtz A.** Lack of evidence for pleiotropic effects of clopidogrel on endothelial function and inflammation in patients with stable coronary artery disease: results of the double-blind, randomized CASSANDRA study. *Clinical Research in Cardiology* 100: 29-36, 2011.
37. **Patti G, Grieco D, Dicuonzo G, Pasceri V, Nusca A, and Di Sciascio G.** High versus standard clopidogrel maintenance dose after percutaneous coronary intervention and effects on platelet inhibition, endothelial function, and inflammation: Results of the ARMYDA-150 mg (antiplatelet therapy for reduction of myocardial damage during angioplasty) randomized study. *Journal of the American College of Cardiology* 57: 771-778, 2011.
38. **Radomski M, Palmer R, and Moncada S.** Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. *The Lancet* 330: 1057-1058, 1987.
39. **Rondina MT, Grissom CK, Men S, Harris ES, Schwertz H, Zimmerman GA, and Weyrich AS.** Whole blood flow cytometry measurements of in vivo platelet activation in critically-ill patients are influenced by variability in blood sampling techniques. *Thrombosis Research* 129: 729-735, 2012.

40. **Rondina MT, Weyrich AS, and Zimmerman GA.** Platelets as cellular effectors of inflammation in vascular diseases. *Circulation Research* 112: 1506-1519, 2013.
41. **Schäfer A, Alp NJ, Cai S, Lygate CA, Neubauer S, Eigenthaler M, Bauersachs J, and Channon KM.** Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. *Arteriosclerosis, Thrombosis, and Vascular Biology* 24: 1720-1726, 2004.
42. **Schäfer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, and Channon KM.** Rapid regulation of platelet activation in vivo by nitric oxide. *Circulation* 109: 1819-1822, 2004.
43. **Sesso HD, Paffenbarger RS, and Lee I-M.** Physical activity and coronary heart disease in men the Harvard Alumni Health Study. *Circulation* 102: 975-980, 2000.
44. **Simon DI, Stamler JS, Loh E, Loscalzo J, Francis SA, and Creager MA.** Effect of nitric oxide synthase inhibition on bleeding time in humans. *Journal of Cardiovascular Pharmacology* 26: 339, 1995.
45. **Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, Parker B, Widlansky ME, Tschakovsky ME, and Green DJ.** Assessment of flow-mediated dilation in humans: a methodological and physiological guideline. *American Journal of Physiology-Heart and Circulatory Physiology* 300: H2-H12, 2011.
46. **Warnholtz A, Ostad MA, Velich N, Trautmann C, Schinzel R, Walter U, and Munzel T.** A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. *Atherosclerosis* 196: 689-695, 2008.
47. **Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, Prescott SM, and Zimmerman GA.** Activated platelets signal chemokine synthesis by human monocytes. *Journal of Clinical Investigation* 97: 1525, 1996.

48. **Williams PC, Coffey MJ, Coles B, Sanchez S, Morrow JD, Cockcroft JR, Lewis MJ, and O'Donnell VB.** In vivo aspirin supplementation inhibits nitric oxide consumption by human platelets. *Blood* 106: 2737-2743, 2005.
49. **Woodman RJ, Playford DA, Watts GF, Cheetham C, Reed C, Taylor RR, Puddey IB, Beilin LJ, Burke V, Mori TA, and Green D.** Improved analysis of brachial artery ultrasound using a novel edge-detection software system. *Journal of Applied Physiology* 91: 929-937, 2001.
50. **Yuan M, Fu H, Ren L, Wang H, and Guo W.** Soluble CD40 ligand promotes macrophage foam cell formation in the etiology of atherosclerosis. *Cardiology* 131: 1-12, 2015.



## **Figure Captions**

### **Figure 1**

Individual responses for MPAs no agonist (NA) vs flow mediated dilation (FMD%) and results of correlation analysis. N=51

### **Figure 2**

Individual responses for platelet PAC-1 binding no agonist (NA) vs flow mediated dilation (FMD%) and results of correlation analysis. N=50

### **Figure 3**

Individual responses for platelet anti-CD62P binding no agonist (NA) vs flow mediated dilation (FMD%) and results of correlation analysis. N=50

**Table 1** General characteristics, anthropometric and dual-energy x-ray absorptiometry (DEXA) and biochemistry variables

	<b>All participants</b>	<b>Male</b>	<b>Female</b>
Age (yrs)	60.6 ± 7.4	57.1 ± 6.3	62.3 ± 7.6
<b><i>Anthropometric data</i></b>			
Height (cm)	166.5 ± 8.0	173.8 ± 4.8	162.2 ± 6.0
Body mass (kg)	76.9 ± 15.8	89.8 ± 11.1	70.0 ± 13.0
Body mass index (kg/m <sup>2</sup> )	27.6 ± 4.5	29.8 ± 3.7	26.6 ± 4.6
Total body fat % (DEXA) n=49	39.5 ± 7.3	34.1 ± 1.2	42.4 ± 6.8
<b><i>Resting HR &amp; blood pressure</i></b>			
Heart rate (bpm)	62 ± 7		
Systolic BP (mmHg)	123 ± 14	127 ± 12	121 ± 14
Diastolic BP (mmHg)	72 ± 9	79 ± 9	69 ± 6
Mean arterial pressure (mmHg)	92 ± 10	98 ± 9	89 ± 8
<b><i>Fasting Biochemistry (mmol/L)</i></b>			
Cholesterol	5.6 ± 0.9	5.5 ± 1.1	5.6 ± 0.7
Triglyceride	1.2 ± 0.7	1.6 ± 0.6	1.1 ± 0.7
LDL-C	3.6 ± 0.8	3.6 ± 0.9	3.6 ± 0.7
HDL-C	1.4 ± 0.3	1.1 ± 0.2	1.5 ± 0.3
Glucose	5.1 ± 0.4	5.3 ± 0.1	5.0 ± 0.1
<b><i>Prescription Medication</i></b>			
	<b><i>N (dual meds)</i></b>		
Any medication	12 (3)	3	9
Blood Pressure medication total	6 (3)	2	4 (3)
<i>Ca channel block</i>	2		
<i>Beta Blocker</i>	1		
<i>Angiotensin II receptor antagonist</i>	3		
Statins	6 (3)	1	5 (3)
Anti-depressant	3		3

Dual energy X-ray absorptiometry *DEXA*, Heart rate *HR*, Blood pressure *BP*, Low-density lipoprotein cholesterol *LDL-C*, High-density lipoprotein cholesterol *HDL-C*. Values are Mean ± SD with exception of Prescription Medication presented as total N. N=51 unless stated otherwise.

**Table 2** Descriptive statistics of FMD and platelet function tests, and results of correlation tests between FMD% and platelet function

	<b>Mean <math>\pm</math> SD</b>		
FMD%	4.6 $\pm$ 2.5		
BD (mm)	3.6 $\pm$ 0.7		
PD (mm)	3.8 $\pm$ 0.7		
<b>Platelet Variable %</b>		<b>R=</b>	<b>P=</b>
MPA NA	4.1 $\pm$ 1.4	0.193	0.175
MPA ADP1.5 $\mu$ M	47.8 $\pm$ 16.8	-0.128	0.369
MPA AA10 $\mu$ g/ml	20.8 $\pm$ 25.3	-0.122	0.396
MPA Coll 1.5 $\mu$ g/ml	5.3 $\pm$ 5.5	0.136	0.340
PAC-1 NA (n=50)	4.7 $\pm$ 5.4	-0.113	0.433
PAC-1 AA10 $\mu$ g/ml (n=50)	23.3 $\pm$ 17.3	-0.045	0.755
PAC-1 Coll 1.5 $\mu$ g/ml	22.3 $\pm$ 20.6	0.174	0.223
CD62P NA (n=50)	1.8 $\pm$ 1.4	-0.078	0.591
CD62P ADP1.5 $\mu$ M	58.7 $\pm$ 19.1	-0.237	0.094
CD62P AA10 $\mu$ g/ml (n=50)	13.5 $\pm$ 11.8	-0.142	0.324
CD62P Coll 1.5 $\mu$ g/ml	8.8 $\pm$ 10.1	-0.077	0.591

FMD *Flow mediated dilation*, BD *baseline diameter*, PD *peak diameter*,  
MPA *Monocyte-platelet aggregate* MPA, No agonist NA, Adenosine  
diphosphate ADP, Arachidonic acid AA, Collagen Coll. N=51 unless  
stated otherwise.

**Table 3** Results of partial correlation tests between FMD% and platelet function accounting for the potential influence of co-variables

<b>Platelet Variable</b>	<b>R=</b>	<b>P=</b>
MPA NA	0.119	0.484
MPA ADP1.5 $\mu$ M	-0.071	0.675
MPA AA10 $\mu$ g/ml	0.015	0.928
MPA Coll 1.5 $\mu$ g/ml	-0.091	0.592
PAC-1 NA (n=50)	-0.075	0.664
PAC-1 AA10 $\mu$ g/ml (n=50)	-0.155	0.368
PAC-1 Coll 1.5 $\mu$ g/ml	-0.005	0.975
CD62P NA (n=50)	0.066	0.704
CD62P ADP1.5 $\mu$ M	-0.246	0.143
CD62P AA10 $\mu$ g/ml (n=50)	-0.091	0.598
CD62P Coll 1.5 $\mu$ g/ml	0.034	0.844

FMD *Flow mediated dilation*, Monocyte-platelet aggregate *MPA*, No agonist *NA*, Adenosine diphosphate *ADP*, Arachidonic acid *AA*, Collagen *Coll*. Co-variables include: age, gender, body fat percentage, resting heart rate and blood pressure, fasting glucose and lipids and medication use. N=51 unless stated otherwise.